Compare SGRY & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | BHC |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Canada |
| Employees | N/A | 20300 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2015 | 1996 |
| Metric | SGRY | BHC |
|---|---|---|
| Price | $26.81 | $8.37 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $24.40 | $8.40 |
| AVG Volume (30 Days) | ★ 7.0M | 3.9M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.14 | ★ 423.08 |
| EPS | ★ N/A | N/A |
| Revenue | $1,145,438,000.00 | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $7.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.41 | $4.33 |
| 52 Week High | $27.23 | $9.04 |
| Indicator | SGRY | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 89.82 | 65.87 |
| Support Level | $13.25 | $7.86 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | 0.31 | 0.03 |
| Stochastic Oscillator | 90.62 | 74.42 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.